首页> 外文期刊>Journal of cardiovascular electrophysiology >Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis.
【24h】

Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis.

机译:Beta阻滞剂会影响有室性心律失常风险的患者的微伏T波交替疗法测试吗?荟萃分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Beta-Blockers and Microvolt T-Wave Alternans. Introduction: Results of microvolt T-wave alternans (MTWA) studies vary and may be influenced by whether beta-blocker therapy was withheld prior to MTWA assessment. We conducted a meta-analysis of the predictive value of MTWA screening for ventricular arrhythmic events in primary prevention patients with left ventricular dysfunction and examined whether results differed depending upon whether beta-blocker use was withheld prior to MTWA testing. Methods and Results: Prospective studies that evaluated whether MTWA predicted ventricular arrhythmic events published between January 1980 and September 2008 were identified. Summary estimates for the predictive value of MTWA were derived with random-effects models. Nine studies involving 3,939 patients were identified. Overall, an abnormal MTWA (positive and indeterminate) test was associated with an almost 2-fold increased risk for arrhythmic events (pooled RR = 1.95, 95% CI: 1.29-2.96; P = 0.002). However, significant heterogeneity across studies was observed (P = 0.024). In the 4 studies in which beta-blocker therapy was not withheld prior to MTWA assessment, an abnormal MTWA test was associated with a 5-fold increased risk for arrhythmic events (pooled RR = 5.39, 95% CI: 2.68-10.84; P < 0.001) and was robust to sensitivity analyses. In contrast, the association was much weaker in those studies where the use of beta-blocker therapy was withheld prior to MTWA testing (pooled RR = 1.40, 95% CI: 1.06-1.84; P = 0.02). Conclusions: In primary prevention patients with left ventricular dysfunction, the predictive power of MTWA varied widely, based on whether beta-blocker therapy was withheld prior to its assessment. This observation may explain the inconsistent results of MTWA studies in this population. (J Cardiovasc Electrophysiol, Vol. 21, pp. 1009-1014, September 2010).
机译:Beta-Blockers和微伏T-W Wave Alternans。简介:微伏T波交替蛋白(MTWA)研究的结果各不相同,并且可能受MTWA评估之前是否停用β受体阻滞剂治疗的影响。我们对MTWA筛查对左心功能不全的一级预防患者的室性心律失常事件的预测价值进行了荟萃分析,并根据在MTWA测试之前是否停用β-受体阻滞剂来检查结果是否有所不同。方法和结果:确定了评估MTWA是否预测1980年1月至2008年9月发表的室性心律失常事件的前瞻性研究。使用随机效应模型得出MTWA预测价值的摘要估计。确定了涉及3939名患者的9项研究。总的来说,异常的MTWA(阳性和不确定性)检测与心律失常事件的风险增加了将近2倍有关(合并RR = 1.95,95%CI:1.29-2.96; P = 0.002)。但是,在研究中观察到明显的异质性(P = 0.024)。在4项未进行MTWA评估前不停止使用β受体阻滞剂治疗的研究中,异常MTWA测试与心律失常事件的风险增加了5倍(合并RR = 5.39,95%CI:2.68-10.84; P < 0.001),并且对敏感性分析具有鲁棒性。相反,在那些在MTWA测试之前停止使用β受体阻滞剂治疗的研究中,这种关联要弱得多(合并的RR = 1.40,95%CI:1.06-1.84; P = 0.02)。结论:在评估左心功能不全的一级预防患者中,MTWA的预测能力差异很大,这取决于是否在评估前停用β受体阻滞剂。该观察结果可以解释该人群中MTWA研究的不一致结果。 (J Cardiovasc Electrophysiol,Vol.21,pp.1009-1014,2010年9月)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号